In 2014, the European Medicines Agency (EMA) approved plasma ctDNA testing for epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) [27], followed by the U.S. Food and Drug Administration (FDA) approval of the Epi proColon® (Berlin, Germany) test for CRC screening in 2016 [28]. The gene discussed is EGFR; the disease is colorectal carcinoma.